Auger-electron therapy
Radioactive atoms that spray very short-range electrons, lethal only if the atom sits on or inside the cell's DNA.
Auger emitters such as iodine-125, indium-111 and terbium-161 release cascades of low-energy electrons with nanometre to micrometre range. Delivered into the nucleus they are exquisitely cytotoxic and, unlike alpha emitters, spare neighbouring cells almost entirely. Terbium-161 is closest to clinical use because it can be substituted for lutetium-177 in existing PSMA and somatostatin ligands, with first-in-human work reported; strategies that require true nuclear delivery remain preclinical.
How it works
Electron-capture or internal-conversion decay releases multiple very low-energy electrons; energy deposition is confined to a few nanometres, so proximity to DNA determines lethality.
- Single-cell selectivity, well suited to micrometastases
- Minimal crossfire into normal tissue
- Terbium-161 slots into existing ligand chemistry
- Needs delivery into the nucleus for the pure Auger effect
- Isotope supply and short half-lives
- Dosimetry models built for beta emitters do not apply
Latest papers
topQuery for this technology: (TITLE:"Auger-electron therapy" OR ABSTRACT:"Auger-electron therapy") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Auger-electron therapy, not a curated reading list.